API Holdings PharmEasy Unlisted shares FY24 financial results: Hold or sell?
In this video, we discuss the FY24 financial results of Pharmeasy unlisted shares and provide a personal review on whether to hold or sell Pharmeasy Pre-IPO shares.
API Holding have seen swift decline in revenue by 16.3% from 6644 Cr to 5564 Cr
Further more, Pharmeasy's operating loss has improved from 1540 cr in FY23 to 699 Cr in FY24. Additionally net loss is also decreased from 5212 Cr in FY23 to 2534 Cr in FY24.
Furthermore, Pharmeasy's operating loss has improved, decreasing from ₹1,540 crore in FY23 to ₹699 crore in FY24. Additionally, the net loss reduced significantly, from ₹5,212 crore in FY23 to ₹2,534 crore in FY24.
Based on this performance, we recommend selling Pharmeasy unlisted shares.
Join Us For all the latest updates about startups, preipo and unicorns.
Keep yourself updated with the market situation.
Join us on Facebook
Contact us at +91 7065560002 via Whatsapp/Normal call
Or Mail us at help@planify.in
Download the app for easy access. Links are given below: